Day 1

ISAR-CLOSURE: FemoSeal and ExoSeal versus manual compression after femoral access

solaci
solaci
529
0

Previous studies with vascular closure devices showed shorter hemostasis and less downtime post-procedure. This study compared the safety and efficacy of two vascular closure devices (FemoSeal and ExoSeal) versus manual compression. The work included 4524 patients undergoing diagnostic coronary angiography using a 6 Fr introducer, randomized 1: 1: 1 to FemoSeal, ExoSeal or manual compression. Both closures were not inferior to the manual compression in terms of vascular access complications. The FemoSeal trended lower vascular complications and length of the hemostasis than ExoSeal. 

5_stefanie_schulz
Stefanie Schulz
2014-09-14

Original title: A Prospective, Randomized Trial of Two Vascular Closure Devices Versus Manual Compression After Femoral Artery Access.

Previous article
CLEAN-TAVI: transcatheter aortic valve replacement with cerebral protection
Next article
CTO-IVUS: IVUS clinical impact in total occlusions with 2nd generation DES
solaci
solaci

More articles by this author

CLEAN-TAVI: transcatheter aortic valve replacement with cerebral protection

solaci - 0
The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times the mortality of these patients. In the...

PARTNER cohort B: 5-year results of a balloon-expandable valve on inoperable patients

solaci - 0
This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment. The 5-year end points included all-cause mortality,...

CoreValve US Pivotal Trial: 2-year results of the self-expanding valve on inoperable patients

solaci - 0
This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery.  The...

US CoreValve: Cost effectiveness of transcatheter replacement versus surgical replacement in high-risk patients

solaci - 0
Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe aortic stenosis receiving transcatheter valve replacement (TAVR)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 1

CLEAN-TAVI: transcatheter aortic valve replacement with cerebral protection

The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times the mortality of...
solaci -
SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Dr. Juan Manuel Pérez - 0
Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Dr. Juan Manuel Pérez - 0
Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Dr. Juan Manuel Pérez - 0
Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...